4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine
C19H21N9O — CID 130234627
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine
4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine (PubChem CID 130234627) has the molecular formula C19H21N9O and a molecular weight of 391.44 g/mol. Its IUPAC name is 4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine.
Molecular Properties
| Compound Name | 4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine |
|---|---|
| PubChem CID | 130234627 |
| Molecular Formula | C19H21N9O |
| Molecular Weight | 391.44 g/mol |
| Exact Mass | 391.19 |
| IUPAC Name | 4-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-yl]-2-(1H-pyrazol-4-yl)-1H-imidazo[4,5-c]pyridin-6-amine |
| SMILES | COC1CCN(c2nccc(-c3nc(N)cc4[nH]c(-c5cn[nH]c5)nc34)n2)CC1 |
| InChI | InChI=1S/C19H21N9O/c1-29-12-3-6-28(7-4-12)19-21-5-2-13(25-19)16-17-14(8-15(20)26-16)24-18(27-17)11-9-22-23-10-11/h2,5,8-10,12H,3-4,6-7H2,1H3,(H2,20,26)(H,22,23)(H,24,27) |
| InChIKey | URVBEGKTHNYKSX-UHFFFAOYSA-N |
| XLogP | 2.00 |
| TPSA | 134.52 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 391.44 |
| LogP ≤ 5 | 2.00 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130234627 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.